BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In summary, present CML treatment guidelines include EMR at 3 months as the first landmark for evaluating responses to TKI therapy, as BCR-ABLIS levels at this time are key predictors of long-term outcomes for CML patients not only in terms of PFS and of OS but also in terms of the possibility of achieving later on the deep molecular responses that have been associated with additional long-term benefits, including the possibility of the suspension of the TKI therapy.